Receptor.AI "democratizes" automated AI solutions for drug discovery

Artificial Intelligence (AI) in drug discovery is now on a steep rise. A growing number of companies compete to develop new drugs faster, cheaper, and with a much higher success rate by using AI tools at all crucial stages of the drug discovery pipeline. Most of the players in this quickly expanding market are oriented towards big pharma, which is routinely investing billions into drug development. Such a partnership is tempting not only for startup companies but also for established leaders in the field of AI-based drug development because it provides stable multi-year contracts backed up by the financial resources and infrastructure of the pharmaceutical giants. As a result, end-to-end AI-based drug discovery services are tailored for large corporate customers.